Cognizant Q3 Revenue Rises 4.6% to $5.66B; Full-Year EPS Guidance Trimmed to $5.72-$5.79
CTSH sits 67% above its 52-week low of $37.08.
Summary
Cognizant beat the midpoint of Q3 revenue guidance at $5.66B (+4.6%) with adjusted EPS of $1.49, but trimmed full-year adjusted EPS guidance to $5.72-$5.79 and narrowed constant-currency growth to 4.0%-4.4%. Third-quarter bookings fell 7% year over year.
Key Events · Earnings and Guidance · CTSH
-
Q3 Revenue Beats Guidance Midpoint
Revenue of $5,664M rose 4.6% year over year (4.8% in constant currency), above the midpoint of the guidance range; Financial Services grew 12.0% while Health Sciences fell 1.1%.
-
Full-Year EPS Guidance Trimmed
2026 adjusted diluted EPS guidance is now $5.72 to $5.79 (8%-10% growth), versus the $5.70-$5.90 range given with Q2 results; constant-currency revenue growth guidance narrowed to 4.0%-4.4%.
-
Margins Expand on Adjusted Basis
Adjusted operating margin of 16.3% expanded 30 bps year over year, the seventh consecutive quarter of expansion, while GAAP operating margin of 15.4% contracted 60 bps on $51M of Project Leap restructuring charges.
-
Q3 Bookings Decline 7%
Third-quarter bookings fell 7% year over year even as trailing-twelve-month bookings rose 4% to $28.7B, a book-to-bill of roughly 1.3x; the quarter included three deals of $100M or more.
Analysis · CTSH · Technology
The headline beat is real—revenue of $5.66B grew 4.6% year over year and landed above the midpoint of guidance—but the forward numbers carry the weight. Full-year adjusted EPS guidance now sits at $5.72 to $5.79, below the $5.70-$5.90 range the company gave in July, and constant-currency revenue growth was narrowed to 4.0%-4.4%. Adjusted operating margin still expands 30 bps to about 16.1%, and free cash flow of $1.58B through nine months funded $2.3B of buybacks and dividends. Bookings are the soft spot: third-quarter bookings fell 7% year over year even though the trailing-twelve-month total rose 4% to $28.7B, and that TTM figure is what feeds future revenue. Project Leap restructuring costs were also revised up to $180M-$250M from the $230M-$320M range outlined in Q2, with $140M-$160M landing in 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTSH was trading at $62.00 on NASDAQ in the Technology sector, with a market capitalization of approximately $29.9B. The 52-week trading range was $37.08 to $87.03. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.